# RVTY Stock vs the S&P 500: Returns, Risk and Crash History

> Revvity, Inc., healthcare (market value $18.2 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Source: https://www.exent.ai/stocks/rvty · Reviewed by David, Senior Analyst, Exent · Published Nov 10, 2026 · Updated Nov 17, 2026

**What changed since Nov 9, 2026:** 5 new ratings

## Key takeaways

- RVTY returned −10.2% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
- Its 5-year Sharpe ratio was −0.01 against 0.58 for the S&P 500.
- Its deepest crisis drawdown was −63.0% in the global financial crisis (2007–09) (S&P 500: −56.5%).
- Five‑year volatility was 33.9% and beta 1.08.
- 20 analysts rated it in the past year; 30% of their latest calls were Buy.
- RVTY beat earnings estimates in 11 of its last 12 reports; the stock moved 5.7% on average, up or down, around each report.

## Did RVTY beat the S&P 500?

Over the 5 years to Oct 30, 2026, Revvity, Inc. (RVTY) returned **−10.2%** including dividends, versus **+75.9%** for the S&P 500 (SPY). It lagged the index by 86.1 percentage points, or −2.1% a year against +12.0%.

| Period | RVTY | S&P 500 | RVTY per year | S&P 500 per year | Result |
| --- | --- | --- | --- | --- | --- |
| 1 year | +68.2% | +12.0% | +68.2% | +12.0% | Beat |
| 3 years | +91.0% | +87.4% | +24.1% | +23.3% | Beat |
| 5 years | −10.2% | +75.9% | −2.1% | +12.0% | Lagged |
| 10 years | +217.3% | +316.3% | +12.2% | +15.3% | Lagged |

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also [how to beat the S&P 500](https://www.exent.ai/beat-the-market).

RVTY is in the [S&P 500](https://www.exent.ai/stocks/sp-500) (members as of Oct 20, 2026); the list shows every member’s return against the index.

## What Wall Street analysts say about RVTY

In the 12 months to 30 days ago, 20 analysts published 118 ratings on RVTY. Their latest calls were 30% Buy, 70% Hold and 0% Sell. 13 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $151.43 (range $115.00–$200.00), −0.7% from the last price. Remember that the average analyst’s target is hit only about half the time: [how accurate are price targets?](https://www.exent.ai/resources/are-analyst-price-targets-accurate)

| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
| --- | --- | --- | --- |
| Members only | Members only | 5.0★ | 67.1% |
| Members only | Members only | 4.9★ | 59.3% |
| Members only | Members only | 4.9★ | 57.5% |
| [Dan Leonard](https://www.exent.ai/analysts/dan-leonard) | [RBC Capital](https://www.exent.ai/firms/rbc-capital) | 4.8★ | 59.6% |
| [Catherine Ramsey Schulte](https://www.exent.ai/analysts/catherine-ramsey-schulte) | [Robert W. Baird](https://www.exent.ai/firms/robert-w-baird) | 4.8★ | 58.0% |

Other analysts covering RVTY: [Eve Burstein](https://www.exent.ai/analysts/eve-burstein) · [Luke Sergott](https://www.exent.ai/analysts/luke-sergott) · [Vijay Kumar](https://www.exent.ai/analysts/vijay-kumar) · [Daniel Arias](https://www.exent.ai/analysts/daniel-arias) · [Casey Woodring](https://www.exent.ai/analysts/casey-woodring)

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on RVTY are, their live calls and the median target of only the top‑rated analysts are in [Exent Gems](https://www.exent.ai/radar).

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. [Unlock the top 50 analysts](https://www.exent.ai/radar).

## RVTY returns by year vs the S&P 500

RVTY beat the S&P 500 in 4 of the 9 full calendar years shown.

| Year | RVTY | S&P 500 | Difference |
| --- | --- | --- | --- |
| 2026 (to Oct 30, 2026) | +62.7% | +11.7% | +51.0% |
| 2025 | −13.1% | +17.7% | −30.8% |
| 2024 | +2.4% | +24.9% | −22.5% |
| 2023 | −21.9% | +26.2% | −48.1% |
| 2022 | −30.1% | −18.2% | −11.9% |
| 2021 | +40.4% | +28.7% | +11.7% |
| 2020 | +48.2% | +18.3% | +29.9% |
| 2019 | +24.0% | +31.2% | −7.2% |
| 2018 | +7.8% | −4.6% | +12.4% |
| 2017 | +40.8% | +21.7% | +19.1% |

## RVTY risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, RVTY had a Sharpe ratio of **−0.01** against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 33.4% and its beta 1.08: it tended to move about 1.1× as much as the market.

| Metric | RVTY | S&P 500 |
| --- | --- | --- |
| Annual return | −2.1% | +12.0% |
| Volatility (annualized) | 33.4% | 15.5% |
| Sharpe ratio | −0.01 | 0.58 |
| Sortino ratio | −0.01 | 0.91 |
| Max drawdown (month-end) | −58.6% | −23.9% |
| Beta to the S&P 500 | 1.08 | 1.00 |

[Sharpe](https://www.exent.ai/learn/sharpe-ratio) divides return above cash by total volatility; [Sortino](https://www.exent.ai/learn/sortino-ratio) counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

## How RVTY behaved in past crashes

RVTY’s deepest fall in the crises below was **−63.0%** in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

| Crisis | RVTY | S&P 500 | Loss on $100,000 |
| --- | --- | --- | --- |
| Global financial crisis (2007–09) | −63.0% | −56.5% | −$62,950 |
| 2018 trade-war selloff | −26.1% | −20.2% | −$26,110 |
| COVID crash (Feb–Mar 2020) | −29.3% | −34.1% | −$29,280 |
| 2022 inflation bear market | −39.1% | −25.4% | −$39,120 |
| 2025 tariff selloff | −22.4% | −19.0% | −$22,360 |

| Window | RVTY max drawdown |
| --- | --- |
| Last 1 year | −30.1% |
| Last 3 years | −37.2% |
| Last 5 years | −59.0% |
| Last 10 years | −59.2% |

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the [crash test](https://www.exent.ai/tools/crash-test).

## What moves with RVTY, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, RVTY’s correlation with the S&P 500 was **0.50**, with the Nasdaq‑100 0.42, with long Treasuries (TLT) 0.42 and with gold (GLD) 0.11.

Adding a 5% RVTY position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.6%.

| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
| --- | --- | --- | --- |
| [CME](https://www.exent.ai/stocks/cme) | −0.07 | [TMO](https://www.exent.ai/stocks/tmo) | 0.68 |
| [PGR](https://www.exent.ai/stocks/pgr) | −0.06 | [DHR](https://www.exent.ai/stocks/dhr) | 0.66 |
| [WM](https://www.exent.ai/stocks/wm) | −0.03 | [MMM](https://www.exent.ai/stocks/mmm) | 0.52 |
| [PLTR](https://www.exent.ai/stocks/pltr) | −0.01 | [HCA](https://www.exent.ai/stocks/hca) | 0.49 |
| [COP](https://www.exent.ai/stocks/cop) | −0.01 | [MRNA](https://www.exent.ai/stocks/mrna) | 0.47 |

Holdings that are highly correlated behave like one position in a selloff. See [how to find hidden overlap](https://www.exent.ai/resources/is-my-portfolio-diversified).

## Latest RVTY upgrades, downgrades and price‑target changes

| Date | Rating and target | Analyst |
| --- | --- | --- |
| Nov 16 | Target raised Hold Target $165, was $160 | [Casey Woodring](https://www.exent.ai/analysts/casey-woodring) J.P. Morgan |
| Nov 12 | Target raised Hold Target $160, was $120 | [Eve Burstein](https://www.exent.ai/analysts/eve-burstein) Bernstein |
| Nov 4 | Target raised Buy Target $190, was $117 | [Catherine Ramsey Schulte](https://www.exent.ai/analysts/catherine-ramsey-schulte) Robert W. Baird |
| Nov 4 | Target raised Hold Target $175, was $160 | [Luke Sergott](https://www.exent.ai/analysts/luke-sergott) Barclays |
| Nov 4 | Target raised Hold Target $177, was $110 | [Daniel Arias](https://www.exent.ai/analysts/daniel-arias) Stifel Nicolaus |
| Nov 4 | Target raised Hold Target $160, was $155 | [Casey Woodring](https://www.exent.ai/analysts/casey-woodring) J.P. Morgan |
| Nov 3 | Target raised Buy Target $180, was $126 | [Vijay Kumar](https://www.exent.ai/analysts/vijay-kumar) Evercore ISI |
| Nov 3 | Target raised Hold Target $172, was $135 | [Dan Leonard](https://www.exent.ai/analysts/dan-leonard) RBC Capital |
| Oct 16 | Target raised Hold Target $155, was $110 | [Casey Woodring](https://www.exent.ai/analysts/casey-woodring) J.P. Morgan |
| Oct 7 | Target raised Hold Target $160, was $115 | [Luke Sergott](https://www.exent.ai/analysts/luke-sergott) Barclays |
| Oct 5 | New coverage Buy | [Matt Larew](https://www.exent.ai/analysts/matt-larew) William Blair |
| Sep 20 | Target raised Hold Target $140, was $100 | Evie Koslosky Goldman Sachs |

Named analysts’ rating and price‑target changes on RVTY in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in [Exent Gems](https://www.exent.ai/radar). [See all of the latest analyst upgrades and downgrades](https://www.exent.ai/analysts/upgrades).

## Do analysts get RVTY right?

Of the 219 analyst price targets on RVTY set from 2019 until a year ago, **54.3%** were reached within 12 months (data to Oct 20, 2026), 14.3 points below the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 63 days. The median target sat 12.8% above the share price on the day it was set.

Where analysts said RVTY would be by now: a year ago, 7 analysts had a price target on RVTY, and the median of their latest targets was **$106.00**. On Oct 20, 2026 RVTY closed at $156.03, 47.2% above it.

- **54.3%** of targets reached within 12 months

- **63 days** median time to reach a target

- **+47.2%** price now vs the median target set a year ago

| After | Calls | Move on the call | 3 months vs S&P 500 |
| --- | --- | --- | --- |
| Upgrades of RVTY | 12 | +0.3% | −8.3% |
| Upgrades, all stocks | 11,514 | +2.5% | +3.4% |
| Downgrades of RVTY | 8 | −1.7% | −7.3% |
| Downgrades, all stocks | 10,700 | −3.0% | −1.6% |

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on RVTY through Sep 15, 2026; analysts are not named here. [Do analyst upgrades move stocks?](https://www.exent.ai/resources/do-analyst-upgrades-move-stocks)

## How RVTY moves after earnings

RVTY beat the consensus earnings‑per‑share estimate in **11 of its last 12** quarterly reports, through the one on Aug 4, 2026, and the revenue estimate in 9 of 12. From the close before each report to the close after it, the stock moved 5.7% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 5 of the 12 reports. In 6 of the 11 beats the stock still fell.

- **11/12** earnings beats

- **±5.7%** average move per report

- **5/12** reports followed by a rise

| Report | EPS vs estimate | Revenue vs estimate | Stock move |
| --- | --- | --- | --- |
| Aug 4, 2026 | $1.41 vs $1.21 | +1.1% | −0.2% |
| May 5, 2026 | $1.06 vs $1.02 | +1.0% | +14.5% |
| Feb 2, 2026 | $1.70 vs $1.57 | +0.9% | −7.1% |
| Oct 27, 2025 | $1.18 vs $1.14 | −0.1% | −2.5% |
| Jul 28, 2025 | $1.18 vs $1.14 | +2.9% | −8.9% |
| Apr 28, 2025 | $1.01 vs $0.96 | −6.5% | +0.4% |
| Jan 31, 2025 | $1.42 vs $1.37 | +9.6% | −2.5% |
| Nov 4, 2024 | $1.28 vs $1.13 | +0.6% | +4.1% |

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. [How stocks move after earnings](https://www.exent.ai/resources/how-stocks-move-after-earnings)

## Where RVTY’s revenue comes from

In fiscal 2025 (the year to Dec 28, 2025), **9.3%** of RVTY’s $4.6 billion revenue came from China, down from 10.2% in fiscal 2024. By region: Other International 59.5%; United States 24.6%; China 9.3%; Germany 3.9%.

By business, the largest segment was Life Sciences, with 50.1% of $2.9 billion revenue (+14.1% on the year before).

| Segment | Revenue | Share | Growth |
| --- | --- | --- | --- |
| Life Sciences | $1.4 billion | 50.1% | +14.1% |
| Diagnostics | $1.4 billion | 49.9% | −5.1% |

From RVTY’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. [Which S&P 500 companies depend most on China?](https://www.exent.ai/resources/sp-500-china-revenue-exposure)

## Members of Congress who traded RVTY

As of Oct 20, 2026, **5 members of Congress** had disclosed 29 trades in RVTY (19 buys and 10 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated May 4, 2026.

| Trade date | Member | Type | Amount |
| --- | --- | --- | --- |
| May 4, 2026 | [Gilbert Cisneros](https://www.exent.ai/congress/gilbert-cisneros) | Buy | $15,001–$50,000 |
| May 1, 2026 | [Gilbert Cisneros](https://www.exent.ai/congress/gilbert-cisneros) | Buy | $1,001–$15,000 |
| Sep 29, 2025 | [Ro Khanna](https://www.exent.ai/congress/ro-khanna) | Buy | $1,001–$15,000 |
| Sep 12, 2025 | [Gilbert Cisneros](https://www.exent.ai/congress/gilbert-cisneros) | Buy | $1,001–$15,000 |
| Aug 26, 2025 | [Ro Khanna](https://www.exent.ai/congress/ro-khanna) | Sale | $1,001–$15,000 |
| Aug 13, 2025 | [Gilbert Cisneros](https://www.exent.ai/congress/gilbert-cisneros) | Buy | $1,001–$15,000 |
| Jul 23, 2025 | [Gilbert Cisneros](https://www.exent.ai/congress/gilbert-cisneros) | Buy | $1,001–$15,000 |
| Jul 22, 2025 | [Lisa McClain](https://www.exent.ai/congress/lisa-mcclain) | Sale | $1,001–$15,000 |
| Jun 17, 2025 | [Lisa McClain](https://www.exent.ai/congress/lisa-mcclain) | Buy | $1,001–$15,000 |
| Jun 11, 2025 | [Gilbert Cisneros](https://www.exent.ai/congress/gilbert-cisneros) | Buy | $1,001–$15,000 |

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. [See every member’s disclosed trades](https://www.exent.ai/congress)

3 trades in RVTY disclosed in the last 30 days are in Exent Radar.

## Are RVTY insiders buying or selling?

In the 12 months to Oct 20, 2026, RVTY insiders made **no open‑market purchases** and **17 sales** worth $6.0 million, according to SEC Form 4 filings.

The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. [Do insider buys beat the market?](https://www.exent.ai/resources/do-insider-buys-beat-the-market)

## How much of RVTY is sold short?

As of the Sep 30, 2026 settlement date, **6.15%** of RVTY’s float was sold short: 6.3 million shares, or 2.4 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 7.87%. The median across the 997 US stocks Exent tracks was 4.77%, so RVTY is more heavily shorted than most.

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. [The most shorted stocks](https://www.exent.ai/resources/most-shorted-stocks)

## How many institutions own RVTY?

At the end of Q2 2026 (Jun 30, 2026), **555 institutions** reported holding RVTY in 13F filings, up 42 from the quarter before and up from 546 a year earlier. Their reported holdings add up to 103.0% of RVTY’s shares. In the quarter 300 institutions added to their positions and 167 cut them.

- **555** 13F holders

- **101** new positions

- **60** positions closed

- **103.0%** of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. [Which stocks institutions are buying and selling](https://www.exent.ai/resources/institutional-ownership-13f-changes)

## Is RVTY diluting shareholders?

RVTY’s diluted share count **rose 1.0%** over the five fiscal years to fiscal 2025 and fell 7.8% in fiscal 2025 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $22.8 million in fiscal 2025, 0.8% of revenue. RVTY spent $820.8 million buying back shares, a buyback yield of 5.71% of its market value; stock pay equaled 2.8% of the buybacks.

- **−7.8%** share count, 1 year

- **+1.0%** share count, 5 years

- **0.8%** stock pay as % of revenue

- **5.71%** buyback yield

Weighted‑average diluted shares from RVTY’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. [Stock dilution and stock‑based compensation, explained](https://www.exent.ai/resources/stock-dilution-and-stock-based-compensation)

## RVTY financial health scores

In Exent’s Oct 20, 2026 snapshot, RVTY’s Altman Z‑score was **3.28**, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was **8 out of 9**; 20% of scored stocks reach 8 or more.

- **3.28** Altman Z‑score: safe zone

- **8/9** Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. [Which stocks have the highest bankruptcy risk?](https://www.exent.ai/resources/altman-z-score-bankruptcy-risk-stocks)

## What RVTY talks about on earnings calls

On its latest earnings call (Aug 6, 2026), RVTY’s executives and analysts mentioned AI **40 times**, against 26 on the call before (May 5, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was tariffs (14).

| Mentions | Aug ’26 | May ’26 | Feb ’26 | Oct ’25 |
| --- | --- | --- | --- | --- |
| AI | 40 | 26 | 11 | 29 |
| AI agents | 0 | 0 | 0 | 2 |
| Data centers | 0 | 0 | 0 | 0 |
| Tariffs | 14 | 1 | 6 | 5 |
| China | 8 | 35 | 13 | 36 |
| Recession | 0 | 0 | 0 | 0 |

Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. [Which companies talk most about AI?](https://www.exent.ai/resources/ai-mentions-on-earnings-calls)

## Which ETFs hold RVTY?

As of Oct 20, 2026, **42** of the 304 ETFs Exent tracks held RVTY. Its largest weight is in DFAT (Dimensional U.S. Targeted Value ETF), at 0.49% of the fund.

| ETF | Fund | Weight of RVTY |
| --- | --- | --- |
| [DFAT](https://www.exent.ai/etfs/dfat) | Dimensional U.S. Targeted Value ETF | 0.49% |
| [VBR](https://www.exent.ai/etfs/vbr) | Vanguard Small-Cap Value Index Fund ETF Shares | 0.39% |
| [SCHM](https://www.exent.ai/etfs/schm) | Schwab U.S. Mid-Cap ETF | 0.35% |
| [XLV](https://www.exent.ai/etfs/xlv) | State Street Health Care Select Sector SPDR ETF | 0.26% |
| [RSP](https://www.exent.ai/etfs/rsp) | Invesco S&P 500 Equal Weight ETF | 0.24% |
| [VHT](https://www.exent.ai/etfs/vht) | Vanguard Health Care Index Fund ETF Shares | 0.24% |
| DFSV | Dimensional US Small Cap Value ETF | 0.23% |
| [VB](https://www.exent.ai/etfs/vb) | Vanguard Small-Cap Index Fund ETF Shares | 0.22% |

Owning several of these funds stacks the same position. [How much do VOO, QQQ and VTI overlap?](https://www.exent.ai/resources/etf-overlap-voo-qqq-vti)

## The right benchmark for RVTY

Exent matches every holding to the index with the most similar risk. For RVTY that is **MDY**. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read [why the S&P 500 is the wrong benchmark for most portfolios](https://www.exent.ai/resources/why-the-sp-500-is-the-wrong-benchmark).

## Other healthcare stocks

| Ticker | Name | 5‑year return | Volatility (5y) |
| --- | --- | --- | --- |
| [LLY](https://www.exent.ai/stocks/lly) | Eli Lilly and Company | +482.3% | 32.6% |
| [JNJ](https://www.exent.ai/stocks/jnj) | Johnson & Johnson | +92.9% | 16.8% |
| [ABBV](https://www.exent.ai/stocks/abbv) | AbbVie Inc. | +207.1% | 23.5% |
| [EXEL](https://www.exent.ai/stocks/exel) | Exelixis, Inc. | +222.6% | 35.4% |
| [ZBH](https://www.exent.ai/stocks/zbh) | Zimmer Biomet Holdings, Inc. | −28.8% | 26.9% |
| [NBIX](https://www.exent.ai/stocks/nbix) | Neurocrine Biosciences, Inc. | +38.6% | 33.0% |
| [MEDP](https://www.exent.ai/stocks/medp) | Medpace Holdings, Inc. | +187.8% | 49.2% |
| [CRL](https://www.exent.ai/stocks/crl) | Charles River Laboratories International, Inc. | −19.9% | 44.7% |

## Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: [Exent methodology](https://www.exent.ai/methodology).

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

## Check RVTY with Exent Gems

Wall Street’s average RVTY price target is 0.7% below the latest share price. See what the best‑ranked analysts on RVTY say now in Exent Gems.

1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
2. Gems shows who the top‑ranked analysts covering RVTY are, their live calls and the median target of only the top‑rated analysts.
3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product: [Exent Gems](https://www.exent.ai/radar)

Also: [Stress‑test your portfolio with RVTY](https://www.exent.ai/portfolio)

## Frequently asked questions

### Did RVTY beat the S&P 500 over the last 10 years?

No. RVTY returned +217.3% (+12.2% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

### Is RVTY in the S&P 500?

Yes. As of Oct 20, 2026, RVTY (Revvity, Inc.) is one of the 503 stocks in the S&P 500.

### How much did RVTY fall in the 2008 crash?

RVTY fell −63.0% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

### How much did RVTY fall in the COVID crash?

RVTY fell −29.3% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

### How much did RVTY fall in the 2022 bear market?

RVTY fell −39.1% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

### What is RVTY’s Sharpe ratio?

Over the 5 years to Oct 30, 2026, RVTY’s Sharpe ratio was −0.01 and its Sortino ratio −0.01, versus 0.58 and 0.91 for the S&P 500.

### Is RVTY a volatile stock?

RVTY’s 5‑year annualized volatility was 33.9%, higher than the S&P 500’s 17.0%, with a beta of 1.08.

### What is least correlated with RVTY?

Among large US stocks, the lowest correlations with RVTY over the last 60 months were CME (−0.07), PGR (−0.06), WM (−0.03). Its correlation with long Treasuries (TLT) was 0.42 and with gold (GLD) 0.11.

### Does RVTY usually beat earnings estimates?

RVTY beat the consensus earnings-per-share estimate in 11 of its last 12 quarterly reports through Aug 4, 2026, and the revenue estimate in 9 of 12. The stock moved 5.7% on average, up or down, from the close before each report to the close after it.

### How much of RVTY’s revenue comes from China?

In fiscal 2025 (the year to Dec 28, 2025), 9.3% of RVTY’s $4.6 billion revenue came from China, about $426.5 million, down from 10.2% in fiscal 2024. Regions are as RVTY reports them in its annual filings.

### Have members of Congress traded RVTY?

Yes. As of Oct 20, 2026, 5 members of Congress had disclosed 29 trades in RVTY (19 buys and 10 sales) in STOCK Act disclosures filed with the House and Senate.

### What is RVTY’s short interest?

As of the Sep 30, 2026 settlement date, 6.15% of RVTY’s float was sold short (6.3 million shares, 2.4 days to cover), according to FINRA short-interest reports. A year earlier it was 7.87%.

### Is RVTY diluting shareholders?

Yes. RVTY’s diluted share count rose 1.0% over the five fiscal years to fiscal 2025 and fell 7.8% in the latest year. Stock-based compensation was 0.8% of revenue, and buybacks totaled $820.8 million.

---

Educational content, not investment advice. Past performance does not guarantee future results.
